| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 21 | 2023 | 255 | 4.670 |
Why?
|
| Bone Neoplasms | 17 | 2023 | 426 | 3.460 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 60 | 1.160 |
Why?
|
| Biomarkers, Tumor | 9 | 2017 | 1534 | 1.160 |
Why?
|
| Blood Proteins | 3 | 2012 | 124 | 0.950 |
Why?
|
| Gene Expression Profiling | 11 | 2023 | 1757 | 0.870 |
Why?
|
| Telomere Shortening | 1 | 2021 | 33 | 0.740 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2020 | 224 | 0.680 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 146 | 0.660 |
Why?
|
| Proteomics | 3 | 2012 | 506 | 0.650 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 57 | 0.650 |
Why?
|
| Brain Neoplasms | 8 | 2021 | 1316 | 0.640 |
Why?
|
| Proteome | 4 | 2021 | 246 | 0.640 |
Why?
|
| Platelet Factor 4 | 2 | 2017 | 22 | 0.640 |
Why?
|
| Cell Movement | 3 | 2020 | 850 | 0.640 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 189 | 0.630 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 1653 | 0.630 |
Why?
|
| Cancer Survivors | 1 | 2021 | 213 | 0.600 |
Why?
|
| Serum Amyloid A Protein | 1 | 2017 | 29 | 0.550 |
Why?
|
| Systems Biology | 2 | 2018 | 58 | 0.530 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2019 | 193 | 0.530 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 53 | 0.520 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 704 | 0.500 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2015 | 1033 | 0.470 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2011 | 61 | 0.460 |
Why?
|
| Prognosis | 11 | 2022 | 4683 | 0.440 |
Why?
|
| Child | 28 | 2023 | 24609 | 0.430 |
Why?
|
| Cell Line, Tumor | 12 | 2023 | 3422 | 0.420 |
Why?
|
| Medulloblastoma | 5 | 2018 | 548 | 0.380 |
Why?
|
| Adolescent | 19 | 2022 | 19412 | 0.380 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 81 | 0.370 |
Why?
|
| Viral Proteins | 2 | 2004 | 346 | 0.360 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 10 | 0.360 |
Why?
|
| Chemokines, CXC | 1 | 2010 | 37 | 0.340 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 680 | 0.340 |
Why?
|
| Neuroblastoma | 2 | 2013 | 529 | 0.330 |
Why?
|
| Membrane Proteins | 2 | 2017 | 1538 | 0.330 |
Why?
|
| Mice, SCID | 7 | 2020 | 587 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 3 | 2021 | 313 | 0.320 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 275 | 0.310 |
Why?
|
| Transcriptome | 3 | 2023 | 978 | 0.310 |
Why?
|
| Humans | 50 | 2023 | 125025 | 0.310 |
Why?
|
| Cell Proliferation | 7 | 2022 | 2377 | 0.300 |
Why?
|
| Mice | 18 | 2023 | 17711 | 0.300 |
Why?
|
| Repressor Proteins | 2 | 2004 | 827 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2008 | 394 | 0.290 |
Why?
|
| Gene Amplification | 4 | 2015 | 235 | 0.280 |
Why?
|
| Operator Regions, Genetic | 2 | 2004 | 5 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 914 | 0.280 |
Why?
|
| Biomarkers | 5 | 2022 | 3105 | 0.270 |
Why?
|
| RNA, Long Noncoding | 2 | 2022 | 218 | 0.270 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1714 | 0.260 |
Why?
|
| Chromosome Aberrations | 3 | 2008 | 615 | 0.260 |
Why?
|
| Algorithms | 3 | 2013 | 1630 | 0.250 |
Why?
|
| Glioblastoma | 2 | 2021 | 347 | 0.250 |
Why?
|
| Survival Rate | 5 | 2016 | 2051 | 0.250 |
Why?
|
| Ependymoma | 2 | 2022 | 164 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 325 | 0.240 |
Why?
|
| Young Adult | 7 | 2021 | 9054 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 1070 | 0.240 |
Why?
|
| Adult | 11 | 2021 | 29452 | 0.230 |
Why?
|
| Animals | 20 | 2023 | 34205 | 0.230 |
Why?
|
| Escherichia coli | 4 | 1998 | 967 | 0.230 |
Why?
|
| Sarcoma | 1 | 2007 | 184 | 0.230 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 2055 | 0.230 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 101 | 0.230 |
Why?
|
| Langerhans Cells | 2 | 2017 | 21 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 743 | 0.230 |
Why?
|
| Male | 19 | 2021 | 61429 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 734 | 0.220 |
Why?
|
| Computational Biology | 2 | 2017 | 819 | 0.220 |
Why?
|
| Female | 21 | 2021 | 66669 | 0.210 |
Why?
|
| Glycoproteins | 3 | 2020 | 362 | 0.210 |
Why?
|
| Mice, Inbred NOD | 4 | 2018 | 299 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1320 | 0.210 |
Why?
|
| Osteopontin | 2 | 2018 | 49 | 0.210 |
Why?
|
| Child, Preschool | 12 | 2021 | 14150 | 0.210 |
Why?
|
| Survival Analysis | 4 | 2020 | 1496 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3310 | 0.210 |
Why?
|
| Pyridoxal Phosphate | 3 | 1998 | 14 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 1245 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 522 | 0.200 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2022 | 16 | 0.200 |
Why?
|
| DNA | 3 | 2022 | 1606 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 71 | 0.190 |
Why?
|
| Models, Genetic | 2 | 2004 | 760 | 0.190 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 1275 | 0.190 |
Why?
|
| Bacteriophage P22 | 1 | 2001 | 1 | 0.190 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 1086 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2020 | 325 | 0.180 |
Why?
|
| Apoptosis | 6 | 2018 | 1819 | 0.180 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1716 | 0.180 |
Why?
|
| Bacterial Proteins | 2 | 1997 | 887 | 0.180 |
Why?
|
| Radiotherapy | 1 | 2021 | 138 | 0.180 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2021 | 91 | 0.170 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 88 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2022 | 1984 | 0.170 |
Why?
|
| Escherichia coli Proteins | 3 | 1998 | 303 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2017 | 1172 | 0.160 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 79 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 146 | 0.160 |
Why?
|
| Loss of Heterozygosity | 2 | 2013 | 130 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 2 | 2014 | 443 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 256 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 509 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 218 | 0.160 |
Why?
|
| Cytoplasm | 1 | 2020 | 289 | 0.150 |
Why?
|
| Antigens, CD | 3 | 2020 | 429 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2018 | 23 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2020 | 413 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2020 | 623 | 0.150 |
Why?
|
| Digoxin | 1 | 2018 | 43 | 0.150 |
Why?
|
| Cytokines | 2 | 2016 | 1292 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 471 | 0.150 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 29 | 0.150 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2018 | 20 | 0.150 |
Why?
|
| Antigenic Variation | 1 | 2018 | 39 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 1097 | 0.140 |
Why?
|
| Recurrence | 3 | 2022 | 1388 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 151 | 0.140 |
Why?
|
| Receptors, Cyclic AMP | 1 | 1997 | 3 | 0.140 |
Why?
|
| Transferases | 1 | 1997 | 4 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2017 | 27 | 0.140 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1997 | 18 | 0.140 |
Why?
|
| Transaminases | 1 | 1997 | 32 | 0.140 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 1998 | 157 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 483 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 210 | 0.130 |
Why?
|
| Cyclic AMP | 1 | 1997 | 244 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1237 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 2 | 2018 | 249 | 0.130 |
Why?
|
| Suppression, Genetic | 1 | 1996 | 43 | 0.130 |
Why?
|
| Ligases | 1 | 1996 | 47 | 0.130 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 261 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Software | 2 | 2012 | 687 | 0.120 |
Why?
|
| Mitoxantrone | 1 | 2015 | 26 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2006 | 79 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 1294 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 858 | 0.120 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 35 | 0.120 |
Why?
|
| Point Mutation | 1 | 1996 | 350 | 0.110 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 514 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 480 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2017 | 650 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 759 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 880 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 214 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 963 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 37 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2014 | 57 | 0.110 |
Why?
|
| Infant | 9 | 2021 | 12610 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 193 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 84 | 0.100 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2004 | 37 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2013 | 94 | 0.100 |
Why?
|
| Genome, Human | 2 | 2013 | 1293 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1893 | 0.100 |
Why?
|
| Wheat Germ Agglutinins | 1 | 2012 | 14 | 0.100 |
Why?
|
| Transcription, Genetic | 2 | 1997 | 1708 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 692 | 0.100 |
Why?
|
| Glycogen | 1 | 2012 | 63 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 560 | 0.100 |
Why?
|
| Ion Exchange | 1 | 2012 | 5 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5167 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3674 | 0.090 |
Why?
|
| Calibration | 1 | 2012 | 87 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4405 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 257 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 516 | 0.090 |
Why?
|
| Molecular Weight | 1 | 2012 | 382 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2012 | 113 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2022 | 4595 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 812 | 0.090 |
Why?
|
| Cytoskeleton | 1 | 2012 | 169 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2008 | 774 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2012 | 216 | 0.090 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 8 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 2654 | 0.090 |
Why?
|
| Chemokine CXCL6 | 1 | 2010 | 16 | 0.090 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2021 | 874 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 216 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 37 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 626 | 0.090 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 137 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2014 | 2813 | 0.080 |
Why?
|
| Binding Sites | 2 | 2004 | 1303 | 0.080 |
Why?
|
| Epidermis | 1 | 2010 | 62 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 513 | 0.080 |
Why?
|
| Mutation | 6 | 2019 | 5897 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 384 | 0.080 |
Why?
|
| Sequence Analysis, RNA | 2 | 2023 | 372 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 366 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1027 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 681 | 0.080 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2009 | 11 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 47 | 0.080 |
Why?
|
| Blood Cells | 1 | 2019 | 50 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2012 | 760 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 407 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 780 | 0.080 |
Why?
|
| Biopsy | 2 | 2018 | 1242 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2054 | 0.070 |
Why?
|
| Texas | 1 | 2016 | 3571 | 0.070 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2004 | 65 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 670 | 0.070 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 653 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 65 | 0.070 |
Why?
|
| Genes, Bacterial | 2 | 1998 | 210 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2004 | 143 | 0.070 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2006 | 9 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2016 | 4819 | 0.070 |
Why?
|
| Osteochondroma | 1 | 2006 | 5 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2023 | 1053 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2019 | 475 | 0.060 |
Why?
|
| Ribosomal Proteins | 1 | 2006 | 71 | 0.060 |
Why?
|
| Mannose-Binding Lectins | 2 | 2020 | 24 | 0.060 |
Why?
|
| Razoxane | 1 | 2005 | 9 | 0.060 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 261 | 0.060 |
Why?
|
| Middle Aged | 2 | 2021 | 26670 | 0.060 |
Why?
|
| Lectins, C-Type | 2 | 2020 | 71 | 0.060 |
Why?
|
| Twist-Related Protein 1 | 1 | 2005 | 36 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 2083 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 1273 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2007 | 191 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2005 | 288 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2004 | 92 | 0.060 |
Why?
|
| Clone Cells | 1 | 2004 | 167 | 0.060 |
Why?
|
| Cisplatin | 1 | 2005 | 249 | 0.060 |
Why?
|
| Chemokine CXCL9 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2876 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 2181 | 0.050 |
Why?
|
| Hydatidiform Mole | 2 | 1994 | 18 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 41 | 0.050 |
Why?
|
| fas Receptor | 1 | 2023 | 41 | 0.050 |
Why?
|
| Azacitidine | 1 | 2023 | 54 | 0.050 |
Why?
|
| Methotrexate | 1 | 2005 | 336 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2023 | 86 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 398 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2022 | 35 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2017 | 236 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2004 | 372 | 0.050 |
Why?
|
| Uterine Neoplasms | 2 | 1994 | 104 | 0.050 |
Why?
|
| CpG Islands | 1 | 2023 | 330 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2022 | 92 | 0.050 |
Why?
|
| Karyotyping | 2 | 2015 | 319 | 0.050 |
Why?
|
| Dissection | 1 | 2021 | 54 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3597 | 0.050 |
Why?
|
| Models, Biological | 2 | 2017 | 1461 | 0.050 |
Why?
|
| Salmonella | 1 | 2001 | 28 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 4415 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 82 | 0.050 |
Why?
|
| Fluorescence | 1 | 2001 | 96 | 0.050 |
Why?
|
| Genomic Instability | 2 | 2015 | 230 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 69 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 145 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2021 | 73 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2021 | 97 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2001 | 295 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 769 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 291 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 173 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 2020 | 21 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 483 | 0.040 |
Why?
|
| Ceruloplasmin | 1 | 1999 | 15 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2013 | 573 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2014 | 359 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 102 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 2 | 1999 | 150 | 0.040 |
Why?
|
| Placenta | 2 | 1994 | 507 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 1155 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 486 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 505 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 2 | 2014 | 19 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2013 | 444 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 42 | 0.040 |
Why?
|
| Base Sequence | 2 | 2001 | 3107 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 561 | 0.040 |
Why?
|
| Pyridoxal Kinase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1998 | 92 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 140 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2001 | 1084 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 9 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 703 | 0.040 |
Why?
|
| Leucine-Responsive Regulatory Protein | 1 | 1997 | 1 | 0.040 |
Why?
|
| 3-Phosphoshikimate 1-Carboxyvinyltransferase | 1 | 1997 | 2 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 35 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1425 | 0.030 |
Why?
|
| Operon | 1 | 1997 | 50 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1361 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 566 | 0.030 |
Why?
|
| Insulin | 1 | 2022 | 1203 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 62 | 0.030 |
Why?
|
| Risk Factors | 1 | 2011 | 10278 | 0.030 |
Why?
|
| Protein Binding | 1 | 2001 | 1747 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2017 | 170 | 0.030 |
Why?
|
| Iron | 1 | 1999 | 276 | 0.030 |
Why?
|
| Pyridoxaminephosphate Oxidase | 1 | 1996 | 1 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2017 | 131 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 16 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 103 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 63 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2010 | 12269 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.030 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 38 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2015 | 150 | 0.030 |
Why?
|
| Brain | 2 | 2018 | 3012 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 55 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1996 | 528 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 342 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 573 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 538 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 677 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2015 | 302 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 547 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 80 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 324 | 0.030 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1993 | 4 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1994 | 216 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 725 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 306 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2018 | 8272 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 625 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 402 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 206 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 508 | 0.020 |
Why?
|
| Trophoblasts | 1 | 1993 | 113 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 241 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2011 | 58 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 56 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 60 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 879 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 802 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2413 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 91 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 1591 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 737 | 0.020 |
Why?
|
| Diploidy | 1 | 2008 | 36 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1701 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 16334 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1997 | 2603 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 419 | 0.020 |
Why?
|
| Aged | 1 | 2004 | 19653 | 0.020 |
Why?
|
| Genes, myc | 1 | 2006 | 105 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 463 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2006 | 119 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 83 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 605 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 623 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 825 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 672 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 651 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 1109 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2004 | 144 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 6122 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 222 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1994 | 263 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 1550 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 3889 | 0.010 |
Why?
|
| Apoproteins | 1 | 1999 | 18 | 0.010 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 1999 | 7 | 0.010 |
Why?
|
| Gestational Age | 2 | 1994 | 1169 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 281 | 0.010 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 1998 | 26 | 0.010 |
Why?
|
| Genomics | 1 | 2004 | 1520 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 704 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 257 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 2709 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 1747 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 472 | 0.010 |
Why?
|
| Pregnancy | 2 | 1994 | 7215 | 0.010 |
Why?
|
| Phenotype | 1 | 1999 | 4266 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 6296 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 1021 | 0.000 |
Why?
|